Please login to the form below

benralizumab

This page shows the latest benralizumab news and features for those working in and with pharma, biotech and healthcare.

Tecentriq’s triple negative breast cancer use among key CHMP nods

The company also received a positive opinion for a new self-administration option for Fasenra (benralizumab) via a pre-filled, single-use auto-injector, rivalling similar moves from GSK and its

Latest news

GSK’s Nucala gets boost with self-administration approval

Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).
AZ says dropping MedImmune will help ‘streamline’ its R&D

The Gaithersburg, Maryland-headquartered company is the source of a chunk of AZ’s biologics pipeline, including cancer immunotherapy Imfinzi (durvalumab) and severe asthma drug Fasenra (benralizumab) that were both highlighted
Cancer drugs and China sustain AZ’s return to growth

Among these, severe asthma therapy Fasenra (benralizumab) shrugged off a tough competitive environment to post $297m in sales in its first full-year on the market despite going toe-to-toe
AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'. NICE has recommended the use of AstraZeneca’s severe asthma treatment Faserna (benralizumab) after the company revised its initial pricing offer. ... Benralizumab could offer an easier method of administration
AZ says target of $45bn sales by 2023 still achievable

In respiratory, interleukin-5 inhibitor Fasenra (benralizumab) – which came to market after rival drugs from GlaxoSmithKline and Teva - is doing “extremely well”, said Soriot, capturing the lion’s share of new

More from news
Approximately 8 fully matching, plus 39 partially matching documents found.

Latest Intelligence

Deal Watch March 2017

In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)
Pharma deals in July 2015

In Japan, AZ paid $45m for an option with Kyowa Hakko Kirin to commercialise benralizumab (currently in phase III for treatment of severe uncontrolled asthma and COPD) in Japan.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director – UK Office: Excellent salary and benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Account Director, Healthcare Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...